CTOs on the Move

Aruna Biomedical

www.arunabio.com

 
ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body`s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Aruna Biomedical raised $13M on 07/24/2019
Aruna Biomedical raised $10.8M on 04/14/2021

Similar Companies

VIRxSYS Corporation

VIRxSYS Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bolt Biotherapeutics

Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman`s Lab at Stanford University, which demonstrated complete cures in numerous cancer models.

Lyell

We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for solid tumor cancers.

Ludesi

Ludesi is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Contrafect

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.